CalciMedica Inc (CALC) Stock AnalysisCALCStock AnalysisCalciMedica Inc

CalciMedica, Inc. is a clinical-stage biopharmaceutical company. The Company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for inflammatory and immunologic diseases. The Company's technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury. Its lead product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The Company is conducting a Phase IIb trial (called CARPO) for acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS), as well as supporting the ongoing Phase I/II asparaginase-induced pancreatic toxicity (AIPT) study (called CRSPA). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

CalciMedica Inc is not a good buy right now due to its current price of $0.4644, a very low RSI of 18.103 indicating oversold conditions, and a significant year-to-date change of -93.11%. The company is facing substantial financial challenges, with a net income loss of $7.65 million in Q2 2026 and a negative EPS of -0.45. The main risk is the company's ongoing financial instability, highlighted by a high debt to equity ratio of 166.88% in Q2 2026, which could further deteriorate investor confidence.